OrbiMed, a leading investment firm focused on the healthcare sector, announced the closing of OrbiMed Private Investments VI, LP, its sixth venture capital fund, with $950 million in limited partner commitments. Investors in the fund include some of the preeminent medical research institutions globally, along with leading endowments, foundations and sovereign wealth funds.
OrbiMed Advisors was founded by the legendary Samuel D. Isaly, the firm’s Managing Partner. Despite being a paraplegic since high-school as a result of a wrestling accident, he became one of the world’s most recognized healthcare fund managers and has been active in global healthcare investing and analysis since 1968 when he joined Chase Manhattan Bank in New York. During his career, he has been a pharmaceutical analyst with Chase Manhattan Bank, Merrill Lynch, Legg Mason, and S.G. Warburg. Mr. Isaly launched OrbiMed’s asset management business in 1989. Mr. Isaly has a B.A. in Economics from Princeton University and a M. Sc. (Econ.) from The London School of Economics.
Consistent with its predecessor funds, the new fund will invest in all stages and sectors of the healthcare industry, with a focus on biopharmaceuticals, medical devices, diagnostics and healthcare IT companies located in North America and Europe. The new fund is expected to invest in approximately 30 portfolio companies in amounts generally ranging from $10 million to $75 million.
Carl Gordon, a Partner at OrbiMed and Co-Head of Global Private Equity, noted, “The increasing pace of translation of science to medicine creates exciting opportunities for the Fund in areas such as oncology, central nervous system disease, and gene editing.”
“With this Fund we plan to accelerate our collaborations with leading life sciences entrepreneurs, strategic companies, research institutions and physicians, to drive the creation of novel therapies that address unmet medical needs,” commented Jonathan Silverstein, also an OrbiMed Partner and Co-Head of Global Private Equity.
OrbiMed is a leading investment firm dedicated to the healthcare sector, with over $16 billion in assets under management. OrbiMed invests globally across the spectrum of healthcare companies, from venture capital start-ups to large multinational companies utilizing a range of private equity funds, public equity funds, royalty/debt funds and other investment vehicles. Founded in 1989, OrbiMed maintains its headquarters in New York City, with additional offices in San Francisco, Shanghai, Mumbai and Herzliya.
As the largest investment firm dedicated to the healthcare sector globally, OrbiMed seeks to be a capital provider of choice. OrbiMed has the flexibility to provide equity and debt capital along with the global team resources required to be an exceptional long-term partner for building world-class healthcare companies.
OrbiMed’s Israel private equity strategy invests in the full spectrum of Israeli life sciences innovation including pharmaceuticals, biotechnology, medical devices and diagnostics. Portfolio companies can range from seed stage to commercial growth equity. OrbiMed’s dedicated local team brings a strong combination of operating, scientific and business experience to help companies develop successfully.
OrbiMed’s Asia private equity strategy is focused on opportunities in China and India across all sectors of healthcare, including healthcare services. Led by a dedicated team based in Shanghai and Mumbai, OrbiMed is able to combine the strengths of its local team with the resources of its global platform to assist companies in Asia with their growth objectives.
North America and Europe: OrbiMed has been an active investor in healthcare private equity since 1993. Our private equity strategy is opportunistic and balanced, with investments across all stages of development. OrbiMed is usually the lead investor in its portfolio companies and seeks an active role in creating value at our portfolio companies.